### Mefloquine

**Indication**: Malaria due to *Plasmodium falciparum*  
**ICD11 code**: 1F40

**INN**: Mefloquine

**Medicine type**: Chemical agent

**List type**: Core (EML)  
**EMLc**

**Formulations**: Oral > Solid: 250 mg tablet (hydrochloride)

**EML status history**:  
- First added in 1991 ([TRS 825](https://www.who.int/medicines/topics/patients/essentialmedicines/EN_WHOTRS825_20150922.pdf))  
- Changed in 2007 ([TRS 950](https://www.who.int/medicines/topics/patients/essentialmedicines/EN_WHOTRS950_20150922.pdf))

**Sex**: All

**Age**: Also recommended for children

**Age restriction**: > 3 months

**Weight restriction**: > 5 kg

**Therapeutic alternatives**: The recommendation is for this specific medicine

**Patent information**: Patents have expired in most jurisdictions  
[Read more about patents.](https://www.who.int/medicines/ topics/patients/essentialmedicines/EN_WHOTRS825_20150922.pdf)

**Wikipedia**: [Mefloquine](https://en.wikipedia.org/wiki/Mefloquine)  
**DrugBank**: [Mefloquine](https://www.drugbank.ca/drugs/DB00180)

---

**Summary of evidence and Expert Committee recommendations**

Mefloquine was endorsed by the Subcommittee to be included in the EMLc for the prophylactic treatment of malaria with a note to be used in children aged > 3 months or > 5 kg.